Neurocrine Biosciences (NBIX) Amortization - Intangibles (2025 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Amortization - Intangibles of $16.4 million for Q2 2026, up 1540.0% year-over-year from $1.0 million in Q2 2025, and up 1540.0% on a QoQ basis from $1.0 million in Q2 2025.
Neurocrine Biosciences (NBIX) Amortization - Intangibles (2025 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Amortization - Intangibles for 2 years, with the latest figure at $16.4 million in Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.40 Mn |
| Jun 30, 2025 | 1.00 Mn |